Observational study of the persistence antiglaucoma eyedrops to

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/19566
• EU PAS number:
  EUPAS5312
• Study ID:
  19566
• Official title and acronym:
  Observational study of the persistence antiglaucoma eyedrops to
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  Glaucoma is an eye disease leading, if not treated, to progressive, irreversible vision loss. Prevalence of glaucoma in France is around 2% of the population older than 40. Treatment of glaucoma is usually topical ocular hypotensive medication (eye drops), that should be administered at long term. Adherence, and especially persistence, are essential for the success of the treatment. Non- or poor adherence may induce public health and economic consequences.Persistence under hypotensive eye drops medications in glaucoma management is expected to be rather poor (induced by chronical condition and mode of administration) but is not well documented. This study aims to assess in the french population the persistence under different topical ocular hypotensive medications, based on the French national health insurance database (EGB) which contains healthcare reimbursement data of 1/97 of the French population.The objective of the study is to compare the 12-month persistence under different topical ocular hypotensive medications in glaucoma management. It will include the description and the comparison of persistence in glaucoma management between different topical ocular hypotensive treatments 12 months after treatment initiation, the identification of predictive factors for persistent and non persistent patients and the assessment of the prevalence and incidence of topical ocular hypotensive medications in France from 2005 to 2009.
• Study status:
  Finalised

Research institution and networks

Institutions

Université Claude Bernard Lyon 1

Study timelines

Date when funding contract was signed

Actual: 30/06/2010

Study start date

Actual: 31/08/2010

Date of final study report

Actual: 31/03/2011

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable